Sodium Risedronate is one of 21 small molecule programs targeting Bone Fracture. It is currently in Preclinical.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
23 competitors in Bone Fracture
Bayer Aspirin
Zometa
Epidiolex
Fareston
Voltaren
Advil
Ultram
Tylenol
Adrenaline
Xylocaine
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Sources